CARGO Therapeutics, Inc. (CRGX) Price & Analysis

Compare

65 Followers

CRGX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$3.00 - $25.45

Previous CloseN/A

Volume19.28K

Average Volume (3M)2.89M

Market Cap

$216.19M

Enterprise Value$503.14M

Total Cash (Recent Filing)$252.57M

Total Debt (Recent Filing)$578.00K

Price to Earnings (P/E)―

Beta1.27

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-4.66

Shares Outstanding48,364,310

10 Day Avg. Volume2,217,181

30 Day Avg. Volume2,888,827

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap2.33

Enterprise Value/Revenue64.26

Enterprise Value/Gross Profit-102.10

Enterprise Value/Ebitda-3.58

Forecast

1Y Price Target

$5.00

Price Target Upside11.86% Upside

Rating ConsensusHold

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Advancement Of Tri-specific ProgramCargo will continue to advance CRG-023, its tri-specific CAR-T therapeutic candidate, into a Phase 1 dose escalation study.

Pipeline DevelopmentCargo plans to initiate enrollment for the Phase I study evaluating CRG-023, an autologous CAR-T cell therapy that expresses three fully human CAR molecules targeting CD19, CD20, and CD22.

Bears Say

Discontinuation Of Firi-cel TrialCRGX announced surprising and disappointing news and will discontinue the lead Phase II Firi-cel (CD22 CART) due to safety and durability.

Safety ConcernsSafety data showed 18% of patients developed immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome that were Grade 3 or higher, including both Grade 4 and 5.

Workforce ReductionCargo Therapeutics is implementing a workforce reduction of approximately 50% to preserve cash.

CARGO Therapeutics, Inc. News

CARGO Therapeutics Acquired by Concentra Biosciences

CARGO Therapeutics, Inc. ( ($CRGX) ) has shared an announcement. CARGO Therapeutics, Inc. announced that on August 18,...

10d ago

CRGX

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

2M ago

CRGX

HEPA

Cargo Therapeutics price target raised to $5 from $3.70 at Jefferies

Jefferies raised the firm’s price target on Cargo Therapeutics (CRGX) to $5 from $3.70 and keeps a Hold...

2M ago

CRGX

CARGO Therapeutics Announces Merger with Concentra Biosciences

The latest announcement is out from CARGO Therapeutics, Inc. ( ($CRGX) ). On July 7, 2025, CARGO Therapeutics...

2M ago

CRGX

Cargo Therapeutics to be acquired by Concentra for $4.379 per share in cash

CARGO Therapeutics (CRGX) has entered into a definitive merger agreement with Concentra Biosciences, whereby Concentra will acquire CARGO...

2M ago

CRGX

CARGO Therapeutics Transfers Lease to Dren Bio

The latest announcement is out from CARGO Therapeutics, Inc. ( ($CRGX) ). On June 27, 2025, CARGO Therapeutics,...

2M ago

CRGX

CARGO Therapeutics Elects Directors at Annual Meeting

CARGO Therapeutics, Inc. ( ($CRGX) ) has issued an update. On June 18, 2025, CARGO Therapeutics, Inc. held...

2M ago

CRGX

CARGO Therapeutics Stock (NASDAQ:CRGX) Jumps 20% on Buyout Hopes

CARGO Therapeutics Stock ($CRGX) soared after the company announced a 90% workforce reduction and suspended all pipeline development, with...

5M ago

CRGX

CARGO Therapeutics Announces Major Workforce Reduction

An announcement from CARGO Therapeutics, Inc. ( ($CRGX) ) is now available. On March 13, 2025, CARGO Therapeutics...

5M ago

CRGX

Cargo suspends CRG-023 and allogeneic platform, reduces workforce by 90%

Cargo Therapeutics (CRGX) provided an update regarding its ongoing evaluation of strategic options following the discontinuation of FIRCE-1,...

5M ago

CRGX

CARGO Therapeutics, Inc.: Hold Rating Amidst Developmental Stagnation and Future Prospects

William Blair analyst Sami Corwin has maintained their neutral stance on CRGX stock, giving a Hold rating today....

6M ago

CRGX

CARGO Therapeutics Highlights Progress in CAR T Therapy

The latest update is out from CARGO Therapeutics, Inc. ( ($CRGX) ). On February 24, 2025, CARGO Therapeutics,...

6M ago

CRGX

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

7M ago

CRGX

LPTX

Meta Platforms, CVS Health upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

7M ago

CRGX FAQ

What was CARGO Therapeutics, Inc.’s price range in the past 12 months?

CARGO Therapeutics, Inc. lowest stock price was $3.00 and its highest was $25.45 in the past 12 months.

What is CARGO Therapeutics, Inc.’s market cap?

CARGO Therapeutics, Inc.’s market cap is $216.19M.

When is CARGO Therapeutics, Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were CARGO Therapeutics, Inc.’s earnings last quarter?

Currently, no data Available

Is CARGO Therapeutics, Inc. overvalued?

According to Wall Street analysts CARGO Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does CARGO Therapeutics, Inc. pay dividends?

CARGO Therapeutics, Inc. does not currently pay dividends.

What is CARGO Therapeutics, Inc.’s EPS estimate?

CARGO Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does CARGO Therapeutics, Inc. have?

CARGO Therapeutics, Inc. has 48,364,310 shares outstanding.

What happened to CARGO Therapeutics, Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of CARGO Therapeutics, Inc.?

Currently, no hedge funds are holding shares in CRGX

CARGO Therapeutics, Inc. Stock Smart Score

Underperform

Fundamentals

Return on Equity

-65.83%

Trailing 12-Months

Asset Growth

-47.22%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

CARGO Therapeutics, Inc.

CARGO Therapeutics, Inc. (CRGX) is a biotechnology company focused on developing advanced therapies in the field of oncology. The company specializes in creating innovative chimeric antigen receptor T-cell (CAR-T) therapies designed to target and eliminate cancer cells. Operating within the biotechnology and healthcare sectors, CARGO Therapeutics is committed to advancing cancer treatment through cutting-edge research and clinical trials aimed at providing patients with effective and personalized therapeutic options.

CARGO Therapeutics, Inc. (CRGX) Earnings & Revenues

Currently, no data available

Please return soon. This page is being updated.

Historic Earnings Reports

CRGX Stock 12 Month Forecast

Average Price Target

$5.00

▲(11.86% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","7":"$7","12":"$12","17":"$17","22":"$22"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,7,12,17,22],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Oct<br/>2024","9":"Jan<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.19,4.252307692307693,4.314615384615385,4.376923076923077,4.439230769230769,4.501538461538462,4.563846153846154,4.626153846153846,4.688461538461539,4.750769230769231,4.813076923076923,4.875384615384616,4.937692307692307,{"y":5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.19,4.252307692307693,4.314615384615385,4.376923076923077,4.439230769230769,4.501538461538462,4.563846153846154,4.626153846153846,4.688461538461539,4.750769230769231,4.813076923076923,4.875384615384616,4.937692307692307,{"y":5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.19,4.252307692307693,4.314615384615385,4.376923076923077,4.439230769230769,4.501538461538462,4.563846153846154,4.626153846153846,4.688461538461539,4.750769230769231,4.813076923076923,4.875384615384616,4.937692307692307,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":21.63,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.54,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.7,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.86,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.27,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.37,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.9,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.42,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.76,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.12,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.19,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >